| Quarter ₩bn | Revenue | YoY | Operating income | Margin | YoY | Net income | EPS |
|---|---|---|---|---|---|---|---|
| 2026 Q2 | 76.1 | — | 27.6 | 36.3% | — | 24.3 | ₩1,666 |
| 2026 Q1 | 72.1 | — | 25.1 | 34.8% | — | 22.7 | ₩1,557 |
| 2025 Q4 | 72.1 | — | 23.7 | 32.8% | — | 23.3 | ₩1,593 |
| 2025 Q3 | 72.7 | — | 21.9 | 30.1% | — | 18.5 | ₩1,270 |
| Fiscal year ₩bn | Revenue | YoY | Operating income | Margin | YoY | Net income | EPS |
|---|---|---|---|---|---|---|---|
| FY2025 | 287.3 | +6.6% | 92.5 | 32.2% | -0.3% | 81.4 | ₩5,578 |
| FY2024 | 269.4 | +11.2% | 92.8 | 34.4% | +10.9% | 68.7 | ₩4,703 |
| FY2023 | 242.3 | — | 83.6 | 34.5% | — | 74.5 | ₩5,104 |
The latest quarter on file is 2026 Q2. The next one, the Q3 2026 report covering the period to Sep 30, 2026, is due on DART by Nov 14, 2026 — Korean issuers must file quarterly and half-year reports within 45 days of period end and the annual report within 90 days.
Large issuers usually publish preliminary consolidated figures (잠정실적, a fair-disclosure filing with revenue and operating profit only) in the first weeks after the period ends, ahead of the full report. kstock does not know a company's chosen release date; when the preliminary filing arrives it appears under Filings and on this page.
| Symbol | Last Price |
|---|---|
| 476830Rznomics, Inc. | ₩28,200 +6.8% |
| 003850Boryung Corporation | ₩9,040 +1.6% |
| 950260Ingenia Therapeutics Inc.(reg.s) | ₩15,580 -1.5% |
| 085660Chabiotech Co., Ltd. | ₩8,090 +2.1% |
| 476060Onconic Therapeutics, Inc. | ₩16,440 -3.9% |
| 041960Komipharm International Co., Ltd. | ₩9,710 +3.5% |
| 001060JW Pharmaceutical | ₩27,500 +1.3% |
| 456160G2GBIO, Inc. | ₩37,950 +5.7% |
| 019170Shinpoong Pharmaceutical Co., Ltd. | ₩10,010 -0.9% |
| 358570GI Innovation, Inc. | ₩8,090 +6.2% |